Thursday, January 23, 2025

CATEGORY

ICER

ICER to Assess Treatments for Spinal Muscular Atrophy

Key TakeawaysICER to evaluate apitegromab and new evidence for SMA treatments. Public comments on the Draft Scoping Document are open until January 27,...

Barriers to Fair Access in US Drug Coverage

Key TakeawaysICER's fourth annual report highlights notable progress in aligning drug coverage policies with fair access standards. Transparency in coverage policy information and...

ICER Report Highlights Unsupported Drug Price Increases in 2023

Key TakeawaysICER highlights five drugs with unsupported price increases in 2023. These increases cost the US healthcare system $815 million in excess spending. ...

ICER Releases Draft Report on Acute Pain Treatment

Key TakeawaysICER releases a draft evidence report on suzetrigine for acute pain treatment. Public comments are open until January 13, 2025, with a...

Tabelecleucel Shows Promise for Epstein-Barr Virus Cancer Treatment

Key TakeawaysTabelecleucel shows clinical benefits for relapsed/refractory EBV+ PTLD patients. ICER's assessment highlights unmet needs and potential cost-effectiveness thresholds. Pricing benchmarks are set...

ICER to Assess Tolebrutinib for Secondary Progressive MS in 2025

Key TakeawaysICER will evaluate the clinical effectiveness and value of tolebrutinib for Secondary Progressive MS (SPMS). The assessment will be presented at the...

ICER Evaluates Cost-Effectiveness of ATTR-CM Treatments

Key TakeawaysICER’s report confirms that tafamidis, acoramidis, and vutrisiran provide significant health benefits for transthyretin amyloid cardiomyopathy (ATTR-CM). ICER suggests pricing tafamidis and...

New Screening Method for Early Preeclampsia Shows Promising Results in Catalonia

The rapid response report by the Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) suggests a major leap forward in preeclampsia screening. By...

Medicare Set to Include COPD Drugs in Next Round of Price Negotiations, ICER Prepares Evaluation

Key TakeawaysThe next round is expected to target COPD drugs like GSK's Breo Ellipta and Trelegy Ellipta. ICER is preparing a special report...

ICER to Assess New Treatment for Retinitis Pigmentosa

Key TakeawaysICER to assess the value and effectiveness of sonpiretigene isteparvovec for retinitis pigmentosa. Public comments on the Draft Scoping Document are open...

ICER Draft Report Evaluates Treatment for EBV+ PTLD

Key TakeawaysICER released a draft evidence report assessing the effectiveness and value of tabelecleucel for treating Epstein-Barr virus positive post-transplant lymphoproliferative disease. Public...

August 2024 Milestones for Institute for Clinical and Economic Review

The Institute for Clinical and Economic Review (ICER) released important findings related to treatments in the field of anemia for myelodysplastic syndrome (MDS). These...

ICER Publishes Evidence Report on Transthyretin Amyloid Cardiomyopathy Treatments

Key Takeaways:ICER evaluates tafamidis, acoramidis, and vutrisiran for treating transthyretin amyloid cardiomyopathy (ATTR-CM). Tafamidis and acoramidis offer health benefits at a cost-effective price...

ICER Report Highlights Pricing Concerns for Imetelstat in Myelodysplastic Syndrome Treatment

Key Takeaways:ICER's final evidence report indicates that the current pricing of imetelstat does not align with its modest clinical benefits in treating anemia...

July 2024 Milestones for Institute for Clinical and Economic Review

This month, the Institute for Clinical and Economic Review (ICER) has released several important reports and updates. These publications highlight ICER's dedication to assessing...

Latest news